Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Prime Medicine, Inc. ( (PRME) ) is now available.
On July 14, 2025, Prime Medicine, Inc. announced the resignation of Jeremy Duffield, M.D. Ph.D., FRCP from his position as Chief Scientific Officer, effective July 15, 2025. The company plans to enter into a Separation Agreement with Dr. Duffield, providing him with severance benefits, and retain his consulting services until March 31, 2026, during which his equity awards will continue to vest.
The most recent analyst rating on (PRME) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Prime Medicine, Inc. stock, see the PRME Stock Forecast page.
Spark’s Take on PRME Stock
According to Spark, TipRanks’ AI Analyst, PRME is a Neutral.
Prime Medicine, Inc. faces significant financial hurdles with ongoing losses and dependency on external funding. While recent technical indicators show potential for recovery, the stock remains under pressure. The promising preclinical results offer a positive long-term outlook, but the current valuation and financial performance weigh heavily on the overall score.
To see Spark’s full report on PRME stock, click here.
More about Prime Medicine, Inc.
Average Trading Volume: 3,160,117
Technical Sentiment Signal: Buy
Current Market Cap: $571.1M
For an in-depth examination of PRME stock, go to TipRanks’ Overview page.